Literature DB >> 24790213

Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.

Luca Prosperini1, Floriana De Angelis1, Rosanna De Angelis1, Fulvia Fanelli1, Carlo Pozzilli1.   

Abstract

Entities:  

Keywords:  MRI; MULTIPLE SCLEROSIS

Mesh：

Substances：

Year:  2014        PMID： 24790213     DOI： 10.1136/jnnp-2014-307786

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  3 in total

1.  Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Authors:  Luca Prosperini; Francesco Saccà; Cinzia Cordioli; Antonio Cortese; Fabio Buttari; Simona Pontecorvo; Assunta Bianco; Serena Ruggieri; Shalom Haggiag; Vincenzo Brescia Morra; Ruggero Capra; Diego Centonze; Giancarlo Di Battista; Elisabetta Ferraro; Ada Francia; Simonetta Galgani; Claudio Gasperini; Enrico Millefiorini; Massimiliano Mirabella; Carlo Pozzilli
Journal:  J Neurol       Date:  2016-11-22       Impact factor: 4.849

2.  No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.

Authors:  Luca Prosperini; Pietro Annovazzi; Laura Boffa; Maria Chiara Buscarinu; Antonio Gallo; Manuela Matta; Lucia Moiola; Luigina Musu; Paola Perini; Carlo Avolio; Valeria Barcella; Assunta Bianco; Deborah Farina; Elisabetta Ferraro; Simona Pontecorvo; Franco Granella; Luigi M E Grimaldi; Alice Laroni; Giacomo Lus; Francesco Patti; Eugenio Pucci; Matteo Pasca; Paola Sarchielli
Journal:  J Neurol       Date:  2018-09-26       Impact factor: 6.682

3.  Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.

Authors:  Zoë Ygj van Lierop; Luuk Wieske; Marleen Ja Koel-Simmelink; Madhurima Chatterjee; Iris Dekker; Cyra E Leurs; Eline Aj Willemse; Bastiaan Moraal; Frederik Barkhof; Filip Eftimov; Bernhard Mj Uitdehaag; Joep Killestein; Charlotte E Teunissen
Journal:  Mult Scler       Date:  2021-04-23       Impact factor: 6.312
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.